EU GMP Annex 1: Implications for Sterile Cannabis Products

The revised Annex 1 redefines sterile manufacturing standards, with practical consequences for makers of injectable or sterile cannabinoid products.

Context and Why It Matters

The regulatory environment for medical cannabis moves faster than most commercial cycles. Staying current is not a luxury—it is a survival condition for operators and prescribers alike.

Evidence and Current Practice

National authorities slowly converge toward common frameworks, but practical differences remain significant. What complies in one country may be insufficient—or redundant—in another.

Operational Considerations

Local interpretation of international standards (EU GMP, ICH, WHO) varies. Knowing your local regulator and building professional relationships early reduces surprises during inspections and filings.

Bottom Line

Documentary traceability is the common answer to nearly every regulatory requirement. Well-designed digital systems pay their cost during the first serious audit.